Our findings strongly suggest that patients who relapse after first treatment , particularly those infected with HCV genotype 2-3 , or living in countries with no access to the direct acting antiviral drugs for HCV , could be successfully re-treated with standard bi-therapy of PEG-IFN + RBV regimen .